Scan to downloadRIBOMIC Inc. (4591) Earnings Releases & Disclosures
Upcoming
- 2026-11-12 Earnings Announcement
| Date | Type | Title | Files |
|---|---|---|---|
| 2026-11-12 | Earnings Release | Summary of Non-Consolidated Financial Results for the Six Months Ended September 30,2026(Based on Japanese GAAP) | |
| 2026-10-20 | — | RIBOMIC Enters into Technology Evaluation Agreement for DDS Aptamer Asset with a Foreign Biotech Company | |
| 2026-10-06 | — | RIBOMIC Announces Interim Report on the Phase 2 Long-Term Clinical Trial of Umedaptanib Pegol in the Treatment of Achondroplasia | |
| 2026-09-29 | — | [Delayed]RIBOMIC Announces No Safety Concerns After Three Months of 1mg/kg Weekly Treatment with Umedaptanib Pegol in Achondroplasia Phase2 Study | |
| 2026-08-24 | — | RIBOMIC Announces Completion of Clinical Trial Site Establishment for the Phase 3 Clinical Trial of Umedaptanib Pegol in Achondroplasia | |
| 2026-08-13 | Earnings Release | Summary of Non-Consolidated Financial Results for the Three Months Ended June 30 2026(Based on Japanese GAAP) |
TDnet keeps only 31 days; this site accumulates daily and cannot backfill earlier disclosures.